Share this Page:
Growing evidence from America suggests that patients with cancer have better responses to the Moderna COVID-19 vaccine than to the Pfizer-BioNTech vaccine, especially for patients with blood cancers.
Studies have shown a difference in the number of protective antibodies and a better immune response in patients who received the Moderna vaccine compared to the Pfizer-Biontech vaccine.
Also, the National Comprehensive Cancer Network (NCCN) in America has released updated recommendations on COVID-19 vaccination for patients with cancer.
These recommendations clarify that most patients with active cancer or a recent history of cancer should receive 3 doses of an mRNA COVID-19 vaccine as their primary vaccinations, along with 2 booster doses of an mRNA vaccine, for a total of 5 vaccinations.